Eurofins Scientific SE

As of December 31, 2025, Eurofins Scientific SE carries a market capitalization of 11.02B, placing it among publicly traded companies globally. Its enterprise value stands at 14.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Eurofins Scientific SE's next confirmed earnings release is scheduled for March 2, 2027.

As of December 31, 2025, Eurofins Scientific SE has 176.70M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Eurofins Scientific SE maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Eurofins Scientific SE's stock has gained approximately 31.63% over the past 52 weeks. The 50-day moving average sits at 74.85, while the 200-day moving average is 68.01.

As of December 31, 2025, Eurofins Scientific SE holds 791.20M in cash and equivalents against 4.43B in total debt, resulting in a net debt position of 3.20B. Total book value stands at 4.54B, with working capital of 223.90M providing operational flexibility.

Eurofins Scientific SE's most recent stock split took place on November 19, 2020 with a 1:10 split ratio.